More than hangover-busting aspirin will be in order at the biopharma industry’s biggest week in London. The capital will host a gruelling conference double header, beginning with the LSX Inv€$tival Showcase on Monday 13th November, followed by the Jefferies London Healthcare Conference on Tuesday 14th November. With investors and biopharma business leaders descending on the […]
In the latest podcast episode, Optimum Strategic Communications’ Eva Haas gives her thoughts on the trends in the biopharma market for 2023. After the geopolitical upheavals of last year, according to some sources there has been a gradual recovery. For instance an analysis by Clarivate and the BioIndustry Association trade body secured £382 million in […]
Analysts and Banking Edward Sham has left their role as Equity Research Analyst at Peel Hunt Ethan Kuo has left their role as Analyst at V-Bio Ventures Dominic Wilson has left Bryan, Garnier & Co Media Anna Brown has joined Endpoints News as a Reporter Ayisha Sharma has joined Endpoints News as a Reporter […]
Alchemab is a Cambridge biotech that aims to revolutionise drug discovery with a novel alternative to big pharma’s classic “choose a target” approach. Optimum’s Richard Staines caught up with Alchemab’s CEO, Young Kwon, to find out more. The UK has long been a leader in the field of antibody drug technology, and it was British […]
There’s an increasing focus on using drugs to modify the tumour microenvironment, reducing immunosuppression and breaking down the barrier of fibrotic scar tissue that blocks many therapies. Optimum Strategic Communications’ Richard Staines talked to our client iOnctura, about the Company’s plans to use an autotaxin inhibitor to remove this obstacle. Scientists are looking at a […]
